CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

Pharmacogenetics

Volumn 6, Issue 6, 1996, Pages 547-551

  Roh, Hyung Keun ^a,b   Dahl, Marja Liisa ^a   Tybring, Gunnel ^a   Yamada, Hiroshi ^a   Cha, Young Nam ^b   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Inha University School of Medicine   (South Korea)

Author keywords

CYP2C19; Korean; Mephenytoin; Omeprazole; Polymorphism

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; HYDROXYOMEPRAZOLE; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RACE;

ADMINISTRATION, ORAL; ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE;

EID: 0030473384     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199612000-00008     Document Type: Article

References (19)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
2. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990: 12, 415-416.
3. Andersson T, Regårdh CG, Lou YC, Zhang M, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992: 2, 25-31.
4. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995: 57, 662-669.
5. Bertilsson L, Lou YQ, Du YL, Lin Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992: 51, 388-397.
6. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39, 511-518.
7. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a: 269, 15419-15420.
8. de Morals SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46, 594-598.
9. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Liao CL, Zhang LM. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
10. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′) hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985: 19, 483-487.
11. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984: 309, 347-356.
12. Masimirembwa CM, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995: 57, 656-661.
13. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38, 402-408.
14. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996: in press.
15. Relling MV, Ayers D, Heideman RL. Mephenytoin phenotyping: lack of hematological effect and timing of urine collections. Pharmacogenetics 1991: 1, 42-49.
16. Setiabudy R, Chiba K, Kusuka M, Ishizaki T. Caution in the use of 100 mg of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992: 33, 665-666.
17. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang J, Shin JG, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992: 52, 160-169.
18. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press 1992: 657-685.
19. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984: 36, 773-780.